A Study Examining Maintenance Bevacizumab (AvastinÂ®) Monotherapy in Participants With Advanced Lung Adenocarcinoma
This prospective, open-label, single arm, non-interventional study will investigate the effectiveness of bevacizumab monotherapy in participants with lung adenocarcinoma who previously received 4 to 6 cycles of induction platinum doublet plus bevacizumab.
Lung Adenocarcinoma
DRUG: Bevacizumab
Progression-Free Survival (PFS), Defined as Time From First Dose of Maintenance Avastin Treatment Until Disease progression or death from any cause, Baseline up to 40 months
PFS, defined as time from first dose of induction Avastin treatment until disease progression or death from any cause, Baseline up to 40 months|1-year overall survival defined as time from first dose of induction Avastin treatment until death from any cause, 12 months|Percentage of participants by best overall response, Baseline up to 40 months|Percentage of participants with adverse events, Baseline up to 40 months
This prospective, open-label, single arm, non-interventional study will investigate the effectiveness of bevacizumab monotherapy in participants with lung adenocarcinoma who previously received 4 to 6 cycles of induction platinum doublet plus bevacizumab.